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OBJECTIVE — Obesity predisposes individuals to congestive heart failure (CHF) and car-
diovascular disease (CVD). Leptin regulates energy homeostasis, is elevated in obesity, and
inﬂuences ventricular and vascular remodeling. We tested the hypothesis that leptin levels are
associated with greater risk of CHF, CVD, and mortality in elderly individuals.
RESEARCH DESIGN AND METHODS — We evaluated 818 elderly (mean age 79
years, 62% women) Framingham Study participants attending a routine examination at which
plasma leptin was assayed.
RESULTS — Leptin levels were higher in women and strongly correlated with BMI (P 
0.0001). On follow-up (mean 8.0 years), 129 (of 775 free of CHF) participants developed CHF,
187 (of 532 free of CVD) experienced a ﬁrst CVD event, and 391 individuals died. In multiva-
riable Cox regression models adjusting for established risk factors, log-leptin was positively
associated with incidence of CHF and CVD (hazard ratio [HR] per SD increment 1.26 [95% CI
1.03–1.55] and 1.28 [1.09–1.50], respectively). Additional adjustment for BMI nulliﬁed the
association with CHF (0.97 [0.75–1.24]) but only modestly attenuated the relation to CVD
incidence (1.23 [1.00–1.51], P  0.052). We observed a nonlinear, U-shaped relation between
log-leptinandmortality(P0.005forquadraticterm)withgreaterriskofdeathevidentatboth
low and high leptin levels.
CONCLUSIONS — In our moderate-sized community-based elderly sample, higher circu-
latingleptinlevelswereassociatedwithagreaterriskofCHFandCVD,butleptindidnotprovide
incremental prognostic information beyond BMI. Additional investigations are warranted to
elucidate the U-shaped relation of leptin to mortality.
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E
xcess adiposity is a key risk factor for
congestive heart failure (CHF) (1) and
cardiovascular disease (CVD) (2), in
partbecauseitisafundamentalprecursorof
several vascular risk factors including high
bloodpressure,dyslipidemia,andimpaired
glucosehomeostasis.IncreasedBMIisoften
used as a surrogate measure of excess adi-
posity.However,BMIreﬂectsthecombined
mass of adipose and nonadipose tissue (in-
cludingmusclesandbones).Therefore,lep-
tin, an anorexogenic hormone that is
predominantly produced in adipose tissue,
may be a better risk marker for CVD than
current BMI.
Several lines of evidence indicate a pu-
tative role for leptin in cardiac (3) and vas-
cularremodeling(4,5),althoughreportsare
divided on whether leptin has predomi-
nantly adverse or beneﬁcial effects on the
heart (6,7) and the vascular system (4,8,9).
Likewise, clinical studies on the association
with CVD have yielded inconsistent results
(10,11).
Interestingly, previous studies sug-
gested that leptin levels are not only deter-
minedbythecurrentadiposetissuevolume
butalsobytheweighthistoryofanindivid-
ual(12).Leptinmight,therefore,beabetter
marker of CVD risk than current BMI, par-
ticularly in normal-weight individuals with
a history of obesity, who might have sub-
clinical CVD (due to antecedent obesity).
Conversely, because obesity is associated
withrelativeleptinresistancethatoftenper-
sistsafterweightreduction,“current”leptin
levels may misclassify the biological effects
of leptin exposure, leaving BMI with a
stronger association to CVD outcomes (rel-
ative to leptin).
On the basis of the clinical and experi-
mentaldatasummarizedabove,wehypoth-
esized that leptin levels are associated with
the incidence of CHF, CVD, and all-cause
mortality in elderly individuals. We tested
this hypothesis by relating leptin levels to
the occurrence of CVD (including CHF)
anddeathprospectivelyinamoderate-sized
elderly community-based sample; we as-
sessed speciﬁcally whether leptin levels of-
ferincrementalprognosticinformationover
established risk factors and BMI. We also
sought to examine the cross-sectional clini-
cal correlates of leptin and evaluated
whether leptin correlates with measures of
past BMI (i.e., serves as an indicator of an
individual’s weight history).
RESEARCH DESIGN AND
METHODS— The design and the se-
lection criteria of the Framingham Heart
Study have been published elsewhere
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are seen in the Heart Study clinic every 2
years. At each examination, participants
undergo laboratory testing for CVD risk
factors, anthropometry, and an examina-
tion by a physician that includes a stan-
dardized medical history and a physical
examination.Allattendeesatthe22ndex-
amination cycle of the original cohort (re-
ferred to as the “index” examination; n 
1,173) were eligible for the present inves-
tigation; we excluded individuals with
nonavailableleptinlevels(n355).After
exclusions, 818 participants remained el-
igible for the analysis of clinical correlates
and relations to all-cause mortality. For
analyses of new-onset CHF, we excluded
43individualswithprevalentCHFsothat
775 remained eligible. For analyses of
ﬁrst CVD events the participants with
prevalent CVD were excluded (n  286),
which left 532 eligible. All participants
provided written informed consent, and
the study protocol was approved by the
institutional review board at the Boston
University Medical Center.
Leptin assay
At examination cycle 22, blood was drawn
from nonfasting participants, usually be-
tween 1:00 and 2:00 P.M. Plasma leptin lev-
els were measured using a commercial
radioimmunoassay (Linco Research, St.
Louis, MO). The interassay coefﬁcient of
variation ranged from 3.0 to 6.2%. The
lower sensitivity limit was 0.5 ng/ml.
Deﬁnitions of outcome events
All Heart Study participants are under
continuous surveillance for the incidence
of CVD (including CHF) and death. Out-
come events are adjudicated by a team of
three physicians who reviews all relevant
medical information, hospitalization
records, and physician ofﬁce visits using
standardized criteria. A separate group
consistingofneurologistsreviewsandad-
judicates all suspected cerebrovascular
events. Criteria for CVD have been pub-
lished and include coronary heart disease
(CHD) (recognized and unrecognized
myocardial infarction, coronary insufﬁ-
ciency,angina,andCHDdeath),cerebro-
vascular disease (stroke and transient
ischemic attack), intermittent claudica-
tion, and CHF (14). A diagnosis of CHF
requiresthepresenceofatleasttwomajor
criteria or one major and two minor cri-
teriaintheabsenceofaconditionthatcan
explaintheﬁndings.Thesamedeﬁnitions
have been used in the Framingham Heart
Study over the years.
In our primary analyses, we focused
on three end points: incident CHF, CVD,
and total mortality. In secondary analy-
ses,werelatedleptinwithincident“hard”
CVD,acompositeendpointthatincludes
fatal and nonfatal myocardial infarction,
coronary insufﬁciency, stroke, or CHF.
Statistical analyses
Given a right-skewed distribution, leptin
levels were logarithmically transformed.
Weevaluatedthecorrelationoflog-leptin
withBMImeasuredattheindexexamina-
tion, in the decade preceding the exami-
nation and over the interval of 10–20
years preceding the index examination
(averageofavailablevaluesfortherespec-
tive decades). Next, we evaluated the
clinical correlates of log-leptin using
multivariable linear regression. Eligible
covariatesincludedage,sex,BMI,systolic
and diastolic blood pressure, antihyper-
tensive treatment, total-to-HDL choles-
terol ratio, triglycerides, diabetes,
smoking, and prevalent CVD.
Separate analyses were conducted for
eachofthethreeoutcomes.Analysisdem-
onstratedastrikingsexualdimorphismin
leptin levels, as reported previously (15).
Therefore,westandardizedlog-leptinval-
ues separately within sex. We performed
pooled sex analyses relating sex-
standardized log-leptin to the incidence
ofoutcomeeventsbecausewedidnotob-
serve effect modiﬁcation by sex (P  0.75
for interactions for all three outcomes).
We evaluated the cumulative inci-
dence of outcome events for leptin levels
greater than or equal to versus less than
the sex-speciﬁc median value. The as-
sumption of proportionality of hazards
was conﬁrmed. We used Cox regression
to relate log-leptin to each outcome. Two
sets of models were evaluated: 1) with ad-
justment for established risk factors; and
2) with additional adjustment for BMI.
We built models using this hierarchical
schema because leptin is strongly corre-
lated with BMI and also to assess the in-
cremental information provided by leptin
over BMI alone. Covariates in the ﬁrst
model evaluating CHF incidence and
mortality included age, sex, total/HDL
cholesterol, diabetes, systolic and dia-
stolic blood pressure, antihypertensive
treatment, current smoking, history of
atrial ﬁbrillation, and prevalent CVD. For
analyses of CVD incidence, covariates
were similar with the exception that par-
ticipants with prevalent CVD were ex-
cluded. To gain insights into potential
nonlinearity of associations between lep-
tin and risk of outcomes, we examined
generalized additive models using penal-
ized splines.
We tested for effect modiﬁcation by
age, hypertension status, and obesity sep-
arately for each of the outcomes. In sec-
ondary analyses, we related leptin levels
to incidence of a ﬁrst hard CVD event on
follow-up (covariates as noted above for
analyses of CVD). In secondary analyses,
we assessed the association of leptin with
CHF, CVD, and mortality in individuals
with and without a history of obesity (de-
ﬁnedasBMI30kg/m
2atanytimeinthe
25 years preceding baseline examination
cycle 22 at which leptin was assayed).
P  0.05 was used to indicate statis-
tical signiﬁcance.
RESULTS— The baseline characteris-
ticsofourelderlystudysampleareshown
in Table 1. Three-ﬁfths of the sample
comprised women, and there was a high
prevalence of antihypertensive treatment,
diabetes, and CVD.
Clinical correlates of leptin
including relations to antecedent
BMI
Leptin was strongly correlated with BMI
at the index examination (r  0.67, P 
0.0001). More modest correlations were
noted with BMI in the decade preceding
the index examination (average of read-
ings obtained 1–10 years before baseline;
r  0.60, P  0.0001) and with BMI
10–20 years before baseline (r  0.46,
P  0.0001). Of note, BMI at the index
examination was more strongly corre-
lated (relative to leptin) with BMI in the
previous decade (r  0.93, P  0.0001)
andintheprior10-to20-yearperiod(r
0.83, P  0.0001).
In multivariable analyses evaluating
the clinical correlates of log-leptin, BMI
(partial R
2  0.26) and sex (partial R
2 
0.28) were the strongest correlates.
Women (median 17.4 [quartile 1, quar-
tile3:10.6,28.7])hadhigherleptinlevels
than men (7.2 [4.5, 11.4]; P  0.001), as
noted earlier. Positive associations of lep-
tin were also noted with the ratio of total-
to-HDL cholesterol (Table 2). Although
participants with diabetes (13.4 [7.9,
23.2]) had higher leptin levels in unad-
justed analyses than participants without
diabetes (12.6 [6.5, 22.4]), these differ-
ences were no longer statistically signiﬁ-
cant upon adjustment for BMI.
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incidence of CHF
During a mean follow-up of 8.5 years
(range 0.2–10), 129 participants (73
women) developed CHF. Figure A1a
(available in an online appendix at http://
care.diabetesjournals.org/cgi/content/full/
dc08-1596/DC1) shows that the cu-
mulative incidence of CHF in individu-
als with leptin levels greater than or equal
to the sex-speciﬁc median value was
higherthanthatinindividualswithleptin
levels below the median (log-rank P 
0.038). In multivariable models without
BMI, leptin was positively associated with
incident CHF (Table 3, model I). Figure
A1b(availableinanonlineappendix)dis-
plays the results of splines relating leptin
to CHF risk: a continuous gradient of in-
creasing CHF risk is noted without evi-
dence of a threshold. However, the
association of leptin with CHF risk was
rendered nonsigniﬁcant after additional
adjustment for BMI (Table 3, model I).
Association of leptin with CVD and
hard CVD
During a mean follow-up of 7.8 years,
187 participants experienced a ﬁrst CVD
event(121women).FigureA2a(available
in an online appendix) shows a higher
cumulative incidence of CVD events in
individuals with leptin levels greater than
or equal to the sex-speciﬁc median com-
pared with participants with levels below
themedian(log-rankP0.0030).Leptin
was associated with CVD incidence in a
multivariable-adjusted model without
BMI, a ﬁnding conﬁrmed by analysis of
splines (Fig. A2b, available in an online
appendix). However, the relations were
attenuated, becoming borderline statisti-
callysigniﬁcant,uponadjustmentforBMI
(Table 3, model II).
In secondary analyses, leptin levels
were also associated with hard CVD events
(141 events in, on average, 8.3 years of fol-
low-up) in multivariable-adjusted models
without BMI (hazard ratio [HR] 1.26 [95%
CI 1.04–1.52], P  0.016). However, this
association was rendered statistically non-
signiﬁcant upon additional adjustment for
BMI (1.05 [0.83–1.33], P  0.70).
Based on the width of the conﬁdence
intervals presented in Table 3, we can ex-
clude (with 95% conﬁdence) a 24% in-
crease in the hazard of developing CHF
and a 51% increase in the hazard of de-
veloping CVD per 1 SD increase in sex-
standardized log-leptin in models
assessingincrementalcontributionoflep-
tin levels over BMI. More modest incre-
mental associations (over BMI) of leptin
with CHF and CVD outcomes would re-
quire analyses of much larger samples.
Association of leptin levels with
total mortality
During a mean follow-up of 8.0 years, 391
participants(217women)died.Thecumu-
lative incidence of death in participants did
not seem to differ for participants with lep-
tin levels more than or equal to versus less
than the sex-speciﬁc median (log-rank P 
0.55) (Fig. A3a, available in an online ap-
pendix). Overall, leptin levels were not re-
lated to total mortality in multivariable
models without (HR 1.00 [95% CI 0.89–
1.12]) and with (0.97 [0.84–1.12]) adjust-
mentforBMI.Analysesofsplinesrevealeda
U-shaped relation of log-leptin levels with
mortality (Fig. A3b, available in an online
appendix). Adding log-leptin squared into
the model conﬁrmed a signiﬁcant associa-
tion with log-leptin squared and mortality
in multivariable models without (P 
0.002)andwith(P0.005)adjustmentfor
BMI. Given the U-shaped relation of log-
leptin and mortality, we repeated the anal-
ysisexcludingparticipantswhodiedwithin
the ﬁrst year of follow-up (n  19) to ex-
cludethepossibilitythattheassociationbe-
tweenlowerleptinlevelsandmortalitymay
beduetoreversecausality(i.e.,comorbidity
leads to low leptin levels and is associated
with higher mortality). Our results were es-
sentially unchanged in these analyses (P 
0.0099 for log-leptin squared).
To further explore the contributions
of cardiovascular versus noncardiovascu-
lar mortality to the U-shaped relations, in
post hoc analyses we examined the two
outcomes separately. On follow-up, 133
participants died of CVD and 258 of non-
CVD. In multivariable-adjusted models
including BMI, log-leptin squared was
not related to CVD death (P  0.70) but
was associated with non-CVD death (P 
0.006).
Table 1—Baseline characteristics of the study sample
Characteristic Value
Clinical features
Women (%) 62.3
Age (years) 79.0  4.5
Systolic blood pressure (mmHg) 143  21
Diastolic blood pressure (mmHg) 72  11
BMI (kg/m²) 26.8  4.7
Antihypertensive treatment (%) 48.9
Current smoking (%) 8.3
Diabetes (%) 27.4
History of atrial ﬁbrillation (%) 10.6
Prevalent heart failure (%) 5.3
History of CVD (%) 35.0
Biochemical features
Total-to-HDL cholesterol ratio (mg/dl) 4.54  1.51
Leptin (ng/ml) 12.8 (7.0, 22,7)
Log-leptin 2.51  0.81
Dataare%forbinarytraitsandmeansSDforcontinuoustraits,exceptforleptinforwhichdataaremedian
(quartile 1, quartile 3). n  818. Log, natural logarithmically transformed.
Table 2—Clinical determinants of log-leptin in elderly individuals
Variable  SE Partial R² P value
Age 0.007 0.004 0.002 0.071
Male sex 0.918 0.037 0.282 0.0001
BMI 0.094 0.004 0.257 0.0001
Total cholesterol-to-HDL ratio 0.042 0.012 0.005 0.001
History of CVD 0.070 0.038 0.002 0.067
Antihypertensive treatment 0.064 0.036 0.001 0.080
Current smoking 0.119 0.065 0.002 0.067
The regression coefﬁcient indicates the increase in log-leptin per 1-unit increment in the predictor variable,
meaningthat,e.g.,a1-unitincrementinBMIleadstoa0.094-unitincreaseinlog-leptin(1.10innanograms
per milliliter).
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In exploratory analyses, associations of
leptin with CHF and CVD were similar in
participants with (n  270 [33%]) and
without(datanotshown)ahistoryofobe-
sity. Likewise, a U-shaped association of
leptin with mortality was observed in
both subgroups.
CONCLUSIONS
Principal ﬁndings
First, higher circulating leptin levels were
associated with female sex and BMI. Sec-
ond, leptin levels were positively associ-
ated with incident CHF and CVD in
multivariable-adjusted models that did
not adjust for BMI. Upon additional ad-
justment for BMI, the association with
CHF was rendered nonsigniﬁcant, and
the association with CVD was borderline
signiﬁcant (P  0.052). Third, we ob-
served a U-shaped relation of leptin with
total mortality driven primarily by an as-
sociation of leptin with non-CVD mortal-
ity. Finally, although leptin displayed
strong positive correlations with recent
and remote BMI, current BMI displayed
stronger correlations with past BMI (rela-
tive to leptin). These data indicate that
current BMI provides reasonable infor-
mation about the weight history of indi-
viduals, and leptin may not provide
incremental information over BMI.
The attenuation of the relations of lep-
tin to the incidence of CHF and CVD upon
adjustment for BMI can be interpreted in
several ways. Leptin may not offer incre-
mental prognostic information because of
its strong correlation with BMI. It is also
conceivable that leptin is along the causal
pathway from excess adiposity to CVD/
CHF. Indeed, an extensive body of litera-
ture supports a pathogenic role for leptin in
cardiovascularremodeling.Thus,theatten-
uation of the relations of leptin to CVD
upon adjustment for BMI may not exclude
animportantpathogenicroleforthisadipo-
kine.Anotherpossibleinterpretationisthat
covariatesinthemodels(total-to-HDLcho-
lesterol ratio, diabetes, and blood pressure)
maymediatesomeoftheeffectsofleptinon
CVD risk.
The weaker association of leptin with
CHF and CVD (relative to BMI) merits
discussion. Most adults in developed
countries gain weight until their 60s and
then begin to lose weight. In humans,
obesityoccursdespitehigherlevelsoflep-
tin because of relative leptin resistance
that prevents the anorexic effects of this
hormone. Leptin resistance persists after
weight loss, so that levels may remain rel-
atively elevated compared with those in
weight-stable control subjects. Neverthe-
less, when we measured leptin in elderly
adults who are already past their peak
adult weight, it is likely that the plasma
leptin in many of them is spuriously ele-
vated compared with their “true” biologi-
cal state. In contrast, BMI reﬂects current
weightandisthuslesslikelytomisclassify
elderly adults in terms of their physiolog-
ical obesity state. Also, our results under-
score the fact that BMI remains an
important predictor of CVD, notwith-
standing the pathogenic importance of
adipokines, including leptin.
Clinical correlates of leptin:
comparison with the published
literature
OurobservationsthatBMIandfemalesex
are principal determinants of leptin are
consistent with ﬁndings in the literature
(15,16). Women have greater body fat
than men, and adipose tissue is a major
source of leptin, which might explain the
higher leptin levels in women. It has been
suggested that leptin captures the weight
history of individuals (12). We observed
that leptin correlated with the mean BMI
averaged over 0–10 and 10–20 years be-
fore the baseline examination. However,
leptin was not as strongly correlated with
past weight history as current BMI.
Association of leptin levels with CHF
In previous cross-sectional studies, in-
creased levels of leptin and its receptor
were reported in patients with CHF
(17,18). Furthermore, increasing evi-
dence indicates that leptin may modulate
cardiac remodeling (3). In experimental
studies, leptin exhibited a dose-
dependentinhibitionofmyocyteshorten-
ing in ventricular myocytes (19).
Likewise,leptinhadadirecthypertrophic
effectonculturedmyocytes(6).However,
some investigators have highlighted an
antihypertrophic effect of leptin (7,20).
These ﬁndings suggest that leptin has a
cardioprotective role and that increased
levels in patients with cardiac disease
might be a response to cardiac injury or
failure rather than being directly causal.
It is difﬁcult to conclude from the
positive relations of leptin to CHF inci-
dencethatleptinisanimportantmediator
of disease (1) or whether higher levels are
a compensatory response to underlying
cardiacremodeling.Inouranalysis,leptin
did not add incremental predictive infor-
mation beyond current BMI.
Association of leptin levels with
CVD and mortality
Clinical data on the association of leptin
with CVD are inconsistent. In some stud-
ies, leptin was associated with incident
myocardial infarction or coronary artery
disease (10,21), whereas other investiga-
tors did not ﬁnd an association between
leptin and CHD (11).
Experimental data on leptin and vas-
cular remodeling are likewise controver-
sial, with some studies suggesting an
atherogenic effect (4,5) and other reports
indicating a vasculoprotective effect
(9,22). In our analyses, leptin was posi-
tivelyassociatedwithCVDonlyinmodels
that did not include adjustment for BMI.
These data are consistent with the con-
cept that leptin may be an important me-
diatorofobesity-associatedCVDrisk,but
it offers no incremental prognostic infor-
mation over BMI.
We observed a U-shaped relation be-
tween leptin levels and total mortality,
with low and high levels being associated
Table 3—Association of standardized log-leptin with incident outcome events: multivariable
Cox regression models without and with adjustment for BMI
Model
HR per SD increment in
log-leptin (95% CI) P value
I. Incidence of CHF (n  775 at risk)
A. Adjusting for established risk factors* 1.26 (1.03–1.55) 0.024
B. Model A and BMI 0.97 (0.75–1.24) 0.79
II. Incidence of CVD (n  532 at risk)
A. Adjusting for established risk factors† 1.28 (1.09–1.50) 0.003
B. Model A and BMI 1.23 (1.00–1.51) 0.052
SD of log-leptin in men  0.67 and in women  0.70. *Models adjusted for age, sex, systolic and diastolic
bloodpressure,hypertensiontreatment,ratiooftotal-to-HDLcholesterol,diabetes,smoking,historyofatrial
ﬁbrillation,andprevalentCVD(includingmyocardialinfarction).†Modelsadjustedforage,sex,systolicand
diastolic blood pressure, hypertension treatment, ratio of total-to-HDL cholesterol, diabetes, smoking, and
history of atrial ﬁbrillation.
Lieb and Associates
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relation has been described for BMI and
mortality (23,24). Additional analyses
conﬁrmed that the U-shaped relation was
largely driven by the association of lower
and higher leptin levels with noncardio-
vascular mortality. It is conceivable that
low and high leptin levels are a marker of
greater risk of death due to noncardiovas-
cular causes (such as cancer). Such an as-
sociation would parallel the known
associationofbothlowandhighBMIwith
noncardiovascular mortality, including
that due to cancer (23,25). However, the
association of leptin with mortality re-
mained U-shaped after the analyses was
restricted to individuals who survived the
ﬁrst year of follow-up, suggesting that the
results are not confounded by greater
mortality risk in individuals with comor-
bidities and low leptin levels.
Limitations
We must acknowledge the limitations of
our approach. Leptin levels were deter-
mined on nonfasting blood samples, and
diurnal variations in concentrations may
result in random misclassiﬁcation, which
may have biased our results toward the
nullhypothesisofnoassociationbetween
leptin and the outcomes evaluated. Our
datawereobtainedinanelderlysampleof
white individuals of European ancestry.
Thus, the generalizability of our data
to other age-groups or ethnicities is
unknown.
In summary, we observed that leptin
isassociatedpositivelywithincidentCHF
and CVD. However, adjustment for BMI
attenuated these associations, suggesting
that leptin does not offer incremental
prognostic information over BMI. The re-
lationship of leptin with mortality was U-
shaped. Additional studies are warranted
to conﬁrm our ﬁndings.
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